Facebook Icon Print Created with Sketch. Twitter Icon Created with Sketch. Created with Sketch. LinkedIn Icon Green Check Icon Created with Sketch. YouTube Icon Right Arrow Icon Mobile Menu Icon Chevron Right Icon Phone Icon Health Study Area: AutoImmune Disease Health Study Area: AutoImmune Disease Health Study Area: Blood Cancer Health Study Area: Blood Cancer Health Study Area: Cardiovascular Disease Health Study Area: Cardiovascular Disease Health Study Area: Fibrosis Health Study Area: Fibrosis Health Study Area: Gastrointestinal Cancer Health Study Area: Gastrointestinal Cancer Health Study Area: Genitourinary Health Study Area: Genitourinary Health Study Area: Head and Neck Cancer Health Study Area: Head and Neck Cancer Health Study Area: Lung Cancer Health Study Area: Lung Cancer Health Study Area: Melanoma Health Study Area: Melanoma Health Study Area: Women's Cancer Health Study Area: Breast Cancer Health Study Area: Breast Cancer For Caregivers For Caregivers For Clinicians Communities FAQs For Parents For Parents For Patients For Patients Chevron Icon Bookmark Icon Map Icon Share Icon Direction Arrow Icon Direction Arrow Icon Page Icon Location Icon Search Icon External Link Icon Help Icon Help Icon Error Icon Glossary Email Icon Gender Both Gender Both Gender Male Gender Female Created with Sketch. Created with Sketch. Health Study Area: NASH Instagram Created with sketchtool. For Clinicians

Please Log In/Join Now first, and then use this function!

COVID-19 (Coronavirus) Message for Patients

Note: As a result of the current COVID-19 (Coronavirus) restrictions, research sites may incorrectly be listed as recruiting or be delayed in responding to patient inquiries due to possible closures. It is suggested that interested patients awaiting a response or current study patients can contact the research site at the phone number provided to ask about study status or confirm scheduled appointments before arriving. Read more about BMS's response to COVID-19 at www.BMS.com.



A Clinical Research Study is Now Recruiting Adults with B Cell NHL



Those who enroll in the study will be asked to take part in another separate follow-up study so researchers can understand the long-term impact of this treatment for up to 13 years. 

 

About the TRANSCEND FL Study

The purpose of the TRANSCEND FL Study

The purpose of the TRANSCEND FL Study

The TRANSCEND FL clinical research study seeks to determine if the experimental therapy called JCAR017 is effective and safe to treat follicular lymphoma or marginal zone lymphoma, and you may be able to take part.

Clinical research studies aim to evaluate how medications work in the volunteers who take them. Researchers use clinical research studies to:

•  Answer specific health questions
•  Learn about the effects and safety of new study medications
•  Help find new ways of using approved medications 

See If You Prequalify

What does the TRANSCEND FL Study involve?

Researchers are trying to find new ways to treat follicular lymphoma and marginal zone lymphoma, which are two types of indolent B cell non-Hodgkin lymphoma (NHL). Clinical research studies are an important part of this research, and volunteers are vital to these trials. Without clinical trials and volunteer participants, clinical research would not be possible.

The TRANSCEND FL clinical research study is investigating JCAR017’s use in cancer treatment. We are studying CAR T cell therapy to see whether it works with the body’s own immune system to help fight cancer. The TRANSCEND FL Study is looking for adults ages 18 and older who have been diagnosed with follicular lymphoma or marginal zone lymphoma, either of which has returned (relapsed) or has not responded to current or previous treatments (refractory). Approximately 150 participants will be selected.




How long is the study?

  • 26

    months (approximately)

  • 18

    research site visits

Those who enroll in the study will be asked to take part in another separate follow-up study so researchers can understand the long-term impact of this treatment for up to 13 years. 



Available Clinical Trials

Below you will find a clinical trial that is sponsored by Bristol Myers Squibb (BMS). Click the “View Trial Detail” link below to get more information about the trial. From the top of the trial page, click the purple “Pre-Screen Now” button to answer a few questions and find out if you match to the clinical trial. If you are not a match and you are a match for a trial sponsored by another company, you will be shown those trials to consider.



About the study periods

This study will have four cohorts, or patient groups. Eligible participants will be assigned to one of these patient groups depending on the following criteria: if they have follicular lymphoma or marginal zone lymphoma, the number and type of treatments they have received in the past, and how long it took for their lymphoma to return after the last treatment. The study consists of three periods, which are pretreatment, treatment, and posttreatment.

  • Pretreatment

    The study doctor will perform tests to determine if an individual is eligible to enroll in the study, which can take up to two weeks. Those who are eligible and consent to participate will then go through a process called leukapheresis (pronounced loo-ka-fer-ee-ses). During this process, some of the participant’s white blood cells are collected from them. The participant’s blood sample is drawn into a machine that collects some of the body’s T cells (a subset of white blood cells that are part of the immune system and can attack things like infections and cancer cells, but also some healthy cells). Those T cells are then sent to a laboratory-based manufacturing facility, where they are modified to make the participant’s own JCAR017 therapy before being infused into their body.
  • Study Treatment

    Once a participant’s JCAR017 T cells are produced, and if their condition allows them to receive the treatment, they will take part in the study treatment period of this study. During this time, they will receive lymphodepleting chemotherapy, followed by infusion of the JCAR017 T cells. Participants will be closely monitored for four weeks after the JCAR017 T cell infusion.
  • Posttreatment

    The study doctor will continue to assess each participant’s condition closely during the posttreatment period and arrange follow-up visits at approximately 2, 3, 6, 9, 12, 18, and 24 months after the JCAR017 T cell infusion.

We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information

Have questions? Live support is available 24/7 - Call 855-907-3286 or email clinical.trials@bms.com

Have questions? Live support is available 24/7 -
Call 855-907-3286 or email clinical.trials@bms.com